JPMorgan lowered the firm’s price target on Biogen (BIIB) to $175 from $185 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the Q1 report.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Hold Rating: Balancing New Drug Growth with Declining MS Franchise and Safety Concerns
- Biogen’s International Growth and Promising Pipeline Drive Buy Rating
- Biogen price target lowered to $205 from $255 at Oppenheimer
- Biogen price target lowered to $205 from $217 at RBC Capital
- Biogen price target lowered to $146 from $152 at Morgan Stanley